Central nicotinic cholinergic systems: A role in the cognitive dysfunction in Attention-Deficit/Hyperactivity Disorder?

Behavioural Brain Research

Volumn 175, Issue 2, 2006, Pages 201-211

  Potter, Alexandra S ^a   Newhouse, Paul A ^a   Bucci, David J ^b  

^a Vermont College of Medicine   (United States)

^b Lamont Doherty Earth Observatory   (United States)

Author keywords

Acetylcholine; ADHD; Cholinergic; Nicotine; Smoking; Substance abuse

Indexed keywords

2 METHYL 3 (2 PYRROLIDINYLMETHOXY)PYRIDINE; CHOLINERGIC RECEPTOR STIMULATING AGENT; CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; METHYLPHENIDATE; NICOTINE; NICOTINIC AGENT; PSYCHOSTIMULANT AGENT; RIVASTIGMINE;

ATTENTION; ATTENTION DEFICIT DISORDER; AVERSION; BEHAVIOR; BRAIN CORTEX; CHOLINERGIC SYSTEM; CIGARETTE SMOKING; COGNITIVE DEFECT; HUMAN; NEUROCHEMISTRY; NONHUMAN; PRIORITY JOURNAL; REVIEW; UNSPECIFIED SIDE EFFECT; WORKING MEMORY;

ANIMALS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; BRAIN; COGNITION DISORDERS; DOPAMINE; HUMANS; RECEPTORS, NICOTINIC; SMOKING;

EID: 33750993511     PISSN: 01664328     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbr.2006.09.015     Document Type: Review

References (122)

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th ed. U.S. Government Printing Office; 1994.
2. Angold A., and Costello E.J. Developmental epidemiology. Epidemiol Rev 17 (1995) 74-82
3. Angold A., Costello E.J., and Erkanli A. Comorbidity. J Child Psychol Psychiatry Allied Disciplines 40 1 (1999) 57-87
4. Aron A.R., and Poldrack R.A. The cognitive neuroscience of response inhibition: relevance for genetic research in attention-deficit/hyperactivity disorder. Biol Psychiatry 57 (2005) 1285-1292
5. Aron A.R., Dowson J.H., Sahakian B.J., and Robbins T.W. Methylphenidate improves response inhibition in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry 54 (2003) 1465-1468
6. Barkley R.A. Behavioral inhibition, sustained attention, and executive functions: constructing a unifying theory of ADHD. Psychol Bull 121 (1997) 65-94
7. Barkley R.A. Attention-deficit/hyperactivity disorder, self-regulation, and time: toward a more comprehensive theory. J Dev Behav Pediatrics 18 (1997) 271-279
8. Baxter M.G., Holland P.C., and Gallagher M. Disruption of decrements in conditioned stimulus processing by selective removal of hippocampal cholinergic input. J Neurosci 17 (1997) 5230-5236
9. Baxter M.G., Bucci D.J., Holland P.C., and Gallagher M. Impairments in conditioned stimulus processing and conditioned responding after combined selective removal of hippocampal and neocortical cholinergic input. Behav Neurosci 13 (1999) 486-495
10. Beane M., and Marrocco R.T. Norepinephrine and acetylcholine mediation of the components of reflexive attention: implications for attention deficit disorders. Prog Neurobiol 74 (2004) 167-181
11. Bedard A.C., Ickowicz A., Logan G.D., Hogg-Johnson S., Schachar R., and Tannock R. Selective inhibition in children with attention-deficit hyperactivity disorder off and on stimulant medication. J Abnorm Child Psychol 31 (2003) 315-327
12. Biederman J., Farone S.V., Keenan K., Steingard R., and Tsuand M.T. Familial association between attention deficit disorder (ADD) and anxiety disorder. Am J Psychiatry 8 (1991) 633-642
13. Biederman J., Faraone S.V., Spencer T., Wilens T., Norman D., Lapey K.A., et al. Patterns of psychiatric comorbidity, cognition, and psychosocial functioning in adults with attention deficit hyperactivity disorder. Am J Psychiatry 150 (1993) 1792-1798
14. Biederman J., Spencer T., and Wilens T. Evidence-based pharmacotherapy for attention-deficit hyperactivity disorder. Int J Neuropsychopharmacol 7 (2004) 77-97
15. Boonstra A.M., Kooij J.J., Oosterlaan J., Sergeant J.A., and Buitelaar J.K. Does methylphenidate improve inhibition and other cognitive abilities in adults with childhood-onset ADHD?. J Clin Exp Neuropsychol 27 (2005) 278-298
16. Bucci D.J., Holland P.C., and Gallagher M. Removal of cholinergic input to rat posterior parietal cortex disrupts incremental processing of conditioned stimuli. J Neurosci 18 (1998) 8038-8046
17. Burke J.D., Loeber R., and Lahey B.B. Which aspects of ADHD are associated with tobacco use in early adolescence?. J Child Psychol Psychiatry Allied Disciplines 42 (2001) 493-502
18. Butt A.E., and Bowman T.D. Transverse patterning reveals a dissociation of simple and configural association learning abilities in rats with 192 IgG-saporin lesions of the nucleus basalis magnocellularis. Neurobiol Learn Memory 77 (2002) 211-233
19. Castellanos F.X. Neuroimaging studies of ADHD. In: Solanto M.V., Arnsten A.F., and Castellanos F.X. (Eds). Stimulant drugs and ADHD: basic and clinical neuroscience (2001), Oxford University Press, New York 243-258
20. Chiba A.A., Bucci D.J., Holland P.C., and Gallagher M. Basal forebrain cholinergic lesions disrupt increments but not decrements in conditioned stimulus processing. J Neurosci 15 (1995) 7315-7322
21. Clarke P.B.S., and Pert A. Autoradiographic evidence for nicotine receptors on nigrostriatal and mesolimbic dopaminergic neurons. Brain Res 348 (1985) 355-358
22. Cook E.H., Stein M.A., Krasowski M.D., Cox N.J., Olkon D.M., Kieffer J.E., et al. Association of attention-deficit disorder and the dopamine transporter gene. Am J Hum Genet 56 (1995) 993-998
23. Cornoldi C., Marzocchi G.M., Belotti M., Caroli M.G., Meo T., and Braga C. Working memory interference control deficit in children referred by teachers for ADHD symptoms. Child Neuropsychol 7 (2001) 230-240
24. Disney E.R., Elkins I.J., McGue M., and Iacono W.G. Effects of ADHD, conduct disorder, and gender on substance use and abuse in adolescence. Am J Psychiatry 156 10 (1999) 1515-1521
25. Dougherty D.D., Bonab A.A., Spencer T.J., Rauch S.L., Madras B.K., and Fischman A.J. Dopamine transporter density in patients with attention deficit hyperactivity disorder. Lancet 354 (1999) 2132-2133
26. Dumas J.A., Saykin A.J., et al. Muscarinic and nicotinic blockade alters working memory performance and brain activation patterns in older women. 35th Annual Meeting of the Society for Neuroscience. Washington, DC (2005)
27. Durston S., Tottenham N.T., Thomas K.M., Davidson M.C., Eigsti I.M., Yang Y., et al. Differential patterns of striatal activation in young children with and without ADHD. Biol Psychiatry 53 (2003) 817-818
28. Durston S. A review of the biological bases of ADHD: what have we learned from imaging studies?. Mental Retard Dev Disabilities Res Rev 9 (2003) 184-195
29. Felix R., and Levin E.D. Nicotinic antagonist administration into the ventral hippocampus and spatial working memory in rats. Neuroscience 81 (1997) 1009-1017
30. Forster G.L., and Blaha C.D. Laterodorsal tegmental stimulation elicits dopamine efflux in the rat nucleus accumbens by activation of acetylcholine and glutamate receptors in the ventral tegmental area. Eur J Neurosci 12 (2000) 3596-3604
31. Foulds J., Stapleton J., Swettenham J., Bell N., McSorley K., and Russell M.A. Cognitive performance effects of subcutaneous nicotine in smokers and never-smokers. Psychopharmacology 127 (1996) 31-38
32. Freedman R., Coon H., et al. Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus. Proc Natl Acad Sci 94 (1997) 587-592
33. Fritz S.K., Fohr K.J., Boddien S., Berg U., Brucker C., and Mayerhofer A. Functional and molecular characterization of a muscarinic receptor type and evidence for expression of choline-acetyltransferase and vesicular acetylcholine transporter in human granulosa-luteal cells. J Clin Endocrinol Metab 84 (1999) 1744-1750
34. Garzon M., Vaughan R.A., Uhl G.R., Kuhar M.J., and Pickel V.M. Cholinergic axon terminals in the ventral tegmental area target a subpopulation of neurons expressing low levels of the dopamine transporter. J Comp Neurol 410 2 (1999) 197-210
35. Green A., Ellis K.A., Ellis J., Bartholomeusz C.F., Ilic S., Croft R.J., et al. Muscarinic and Nicotinic receptor modulation of object and spatical n-back working memory in humans. Pharmacol Biochem Behav 81 (2005) 575-584
36. Gronier B., Perry K.W., and Rasmussen K. Activation of the mesocorticolimbic dopaminergic system by stimulation of muscarinic cholinergic receptors in the ventral tegmental area. Psychopharmacology 147 (2002) 347-355
37. Grottick A.J., and Higgins G.A. Effect of subtype selective nicotinic compounds on attention as assessed by the five-choice serial reaction time task. Behav Brain Res 117 (2000) 197-208
38. Hahn B., Shoaib M., and Stolerman I.P. Nicotine-induced enhancement of attention in the five-choice serial reaction time task: the influence of task demands. Psychopharmacology (Berl) 162 (2002) 129-137
39. Holland P.C. Brain mechanisms for changes in processing of conditioned stimuli in Pavlovian conditioning: implications for behavior theory. Anim Learn Behav 25 (1997) 373-399
40. Ikemoto S., and Wise R.A. Rewarding effects of the cholinergic agents carbachol and neostigmine in the posterior ventral tegmental area. J Neurosci 22 (2002) 895-904
41. Kent L., Middle F., Hawi Z., Fitzgerald M., Gill M., Feehan C., et al. Nicotinic acetylcholine receptor alpha4 subunit gene polymorphism and attention deficit hyperactivity disorder. Psychiatr Genet 11 (2001) 37-40
42. Kent L., Green E., Holmes J., Thapar A., Gill M., Hawi Z., et al. No association between CHRNA7 microsatellite markers and attention-deficit hyperactivity disorder. Am J Med Genet 105 (2001) 686-689
43. Krause K.H., Dresel S.H., Krause J., Kung H.F., and Tatsch K. Increased striatal dopamine transporter in adult patients with attention deficit hyperactivity disorder: effects of methylphenidate as measured by single photon emission computed tomography. Neurosci Lett 285 (2000) 107-110
44. LaHoste G.J., Swanson J.M., Wigal S.B., Glabe C., Wigal T., King N., et al. Dopamine D4 receptor gene polymorphism is associated with attention deficit hyperactivity disorder. Mol Psychiatry 1 (1996) 121-124
45. Lambert N.M. Hartsough CS Prospective study of tobacco smoking and substance dependencies among samples of adhd and non-adhd participants. J Learn Disabilities 31 (1998) 533-544
46. Lamour Y., Dutar P., and Jobert A. Topographic organization of basal forebrain neurons projecting to the rat cerebral cortex. Neurosci Lett 34 (1982) 117-122
47. Lehmann C. ADHD symptoms respond to cholinergic drugs. Psychiatric News 38 (2003) 25-28
48. Leonard S., and Gault J. DNA variants in the alpha 7 nicotinic recptor gene promoter are associated with schizophrenia. Biol Psychiatry 49 (2001) 166S
49. Levin E.D. Nicotinic receptor subtypes and cognitive function. J Neurobiol 53 (2002) 633-640
50. Levin E.D., Kaplan S., and Boardman A. Acute nicotine interactions with nicotinic and muscarinic antagonists: working and reference memory effects in the 16-arm radial maze. Behav Pharmacol 8 (1997) 236-242
51. Levin E., Wilson W., Rose J., and McEvoy J. Nicotine-haloperidol interactions and cognitive performance in schizophrenics. Neuropsychopharmacology 15 (1996) 429-436
52. Levin E.D., McGurk S.R., Rose J.E., and Butcher L.L. Cholinergic-dopaminergic interactions in cognitive performance. Behav Neural Biol 54 (1990) 271-299
53. Levin E.D., Conners C.K., Sparrow E., Hinton S.C., Erhardt D., Meck W.H., et al. Nicotine effects on adults with attention-deficit/hyperactivity disorder. Psychopharmacology 123 (1996) 55-63
54. Levin E.D., Conners C.K., Silva D., Hinton S.C., Meck W.H., March J., et al. Transdermal nicotine effects on attention. Psychopharmacology 140 (1998) 135-141
55. Levy F., and Swanson J.M. Timing, space and ADHD: the dopamine theory revisited. Aust N Z J Psychiatry 35 (2001) 504-511
56. Logan G.D., Cowan W.B., and Davis K.A. On the ability to inhibit simple and choice reaction time responses: a model and a method. J Exp Psychology: Hum Percept Performance 10 (1984) 276-291
57. Lufi D., Cohen A., and Parish-Plass J. Identifying attention deficit hyperactive disorder with the WISC-R and the Stroop color and word test. Psychol Schools (1990) 28-34
58. Luiten P.G.M., Gaykema R.P.A., Traber J., and Spencer J.D.G. Cortical projection patterns of magnocellular basal nucleus subdivisions as revealed by anterogradely transported Phaseolus vulagris leucoagglutinin. Brain Res 413 (1987) 229-250
59. MacLeod D., and Prior M. Attention deficits in adolescents with ADHD and other clinical groups. Child Neuropsychol 2 (1996) 1-10
60. MacLeod J.E., Potter A.S., Simoni M.K., and Bucci D.J. Nicotine administration enhances conditioned inhibition in rats. Eur J Pharmacol 551 (2006) 76-79
61. Mayerhofer A.N., Dimitrijevic N., and Kunz L. The expression and biological role of the non-neuronal cholinergic system in the ovary. Life Sci 72 (2003) 2039-2045
62. McGaughy J., Everitt B.J., Robbins T.W., and Sarter M. The role of cortical cholinergic afferent projections in cognition: impact of new selective immunotoxins. Behav Brain Res 115 (2000) 251-263
63. Mercugliano M. What is attention-deficit/hyperactivity disorder?. Pediatr Clin North Am 46 5 (1999) 831-843
64. Merlo Pich E., Chiamulera C., and Carboni L. Molecular mechanisms of the positive reinforcing effect of nicotine. Behav Pharmacol 10 6-7 (1999) 587-596
65. Mesulam M.-M., Mufson E.J., Wainer B.H., and Levey A.I. Central cholinergic pathways in the rat: an overview based on an alternative nomenclature (Ch1-Ch6). Neuroscience 10 (1983) 1185-1201
66. Milberger S., Beiderman J., Faraone S.V., Chen L., and Jones J. ADHD is associated with early initiation of cigarette smoking in children and adolescents. J Am Acad Child Adolescent Psychiatry 36 (1997) 37-44
67. Molina B.S., and Pelham W.E. Childhood predictors of adolescent substance use in a longitudinal study of children with ADHD. J Abnorm Psychol 112 (2003) 497-507
68. MTA Cooperative Group. A 14 month randomized clinical trial of treatment strategies of attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 56 (1999) 1073-1086
69. Muir J.L., Everitt B.J., and Robbins T.W. Reversal of visual attentional dysfunction following lesions of the cholinergic basal forebrain by physostigmine and nicotine but not by the 5-HT3 receptor antagonist, ondansetron. Psychopharmacology (Berl) 118 (1995) 82-92
70. Nambu A., Tokuno H., and Takada M. Functional significance of the cortico-subthalamo-pallidal 'hyperdirect' pathway. Neurosci Res 43 (2002) 111-117
71. Newhouse P.A., Potter A., Kelton M., and Corwin J. Nicotinic treatment of Alzheimer's disease. Biol Psychiatry 49 (2001) 268-278
72. Nigg J.T. Is ADHD a disinhibitory disorder?. Psychol Bull 127 (2001) 571-598
73. Nigg J.T. Neuropsychologic theory and findings in attention-deficit/hyperactivity disorder: the state of the field and salient challenges for the coming decade. Biol Psychiatry 57 (2005) 1424-1435
74. Pennington B.F., and Ozonoff S. Executive functions and developmental psychopathology. J Child Psychol Psychiatry Allied Disciplines 37 (1996) 51-87
75. Pomerleau O.F., Downey K.K., Stelson F.W., and Pomerleau C.S. Cigarette smoking in adult patients diagnosed with attention deficit hyperactivity disorder. J Subst Abuse 7 (1995) 373-378
76. Porrino L.J., Rapoport J.L., Behar D., Ismond D.R., and Bunney Jr. W.E. A naturalistic assessment of the motor activity of hyperactive boys. II. Stimulant drug effects. Arch Gen Psychiatry 40 (1983) 688-693
77. Potter A.S., and Newhouse P.A. Effects of acute nicotine administration on behavioral inhibition in adolescents with attention-deficit/hyperactivity disorder. Psychopharmacology 176 (2004) 182-194
78. Potter A.S., and Newhouse P.A. Cognitive effects of acute nicotine and ultra low-dose Mecamylamine in attention-deficit/hyperactivity disorder. Biol Psychiatry 57 (2005) 69S
79. Prendergast M.A., Jackson W.J., Terry Jr. A.V., Decker M.W., Arneric S.P., and Buccafusco J.J. Central nicotinic receptor agonists ABT-418, ABT-089, and (-)-nicotine reduce distractibility in adult monkeys. Psychopharmacology (Berl) 136 (1998) 50-58
80. Prendergast M.A., Terry Jr. A.V., Jackson W.J., Marsh K.C., Decker M.W., Arneric S.P., et al. Improvement in accuracy of delayed recall in aged and non-aged, mature monkeys after intramuscular or transdermal administration of the CNS nicotinic receptor agonist ABT-418. Psychopharmacology (Berl) 130 (1997) 276-284
81. Quay H.C. Inhibition and attention deficit hyperactivity disorder. J Abnorm Child Psychol 25 (1997) 7-13
82. Quik M., Polonskaya Y., Gillespie A., Jakowec M., Lloyd G.K., and Langston J.W. Localization of nicotinic receptor subunit mRNAs in monkey brain by in situ hybridization. J Comp Neurol 425 (2000) 58-69
83. Rapier C., Lunt G.G., and Wonnacott S. Nicotinic modulation of [3h]dopamine release from striatal synaptosomes: pharmacological characterisation. J Neurochem 54 (1990) 937-945
84. Rapoport J.L., Buchsbaum M.S., Weingartner H., Zahn T.P., Ludlow C., and Mikkelsen E.J. Dextroamphetamine. Its cognitive and behavioral effects in normal and hyperactive boys and normal men. Arch Gen Psychiatry 37 (1980) 933-943
85. Rye D.B., Wainer B.H., Mesulam M.-M., Mufson E.J., and Saper C.B. Cortical projections arising from the basal forebrain: a study of cholinergic and noncholinergic components employing combined retrograde tracing and immunohistochemical localization of choline acetyltransferase. Neuroscience 13 (1984) 627-643
86. Saper C.B. Organization of cerebral cortical afferent systems in the rat. I. Magnocellular basal nucleus. J Comp Neurol 222 (1984) 313-342
87. Sarter M., and Bruno J.P. Cognitive functions of cortical acetylcholine: towards a unifying hypothesis. Brain Res Rev 23 (1997) 28-46
88. Sarter M., Bruno J.P., and Givens B. Attentional functions of cortical cholinergic inputs: what does it mean for learning and memory?. Neurobiol Learn Memory 80 (2003) 245-256
89. Sarter M., Hasselmo M.E., Bruno J.P., and Givens B. Unraveling the attentional functions of cortical cholinergic inputs: interactions between signal-driven and cognitive modulation of signal detection. Brain Res Rev 48 (2005) 98-111
90. Schachar R., Tannock R., and Logan G. Inhibitory control, impulsiveness, and attention deficit hyperactivity disorder. Clin Psychol Rev (1993) 721-739
91. Schulz D.W., Loring R.H., Aizenman E., and Zigmond R.E. Autoradiographic localization of putative nicotinic receptors in the rat brain using 125I-neuronal bungarotoxin. J Neurosci 11 (1991) 287-297
92. Sergeant J.A., Oosterlaan J., and van der Meere J. Information processing and energetic factors in attention-deficit/hyperactivity disorder. In: Quay H., and Hogan A. (Eds). Handbook of disruptive behavior disorders (1999), Plenum Press, New York 75-104
93. Sergeant J.A. Modeling attention-deficit/hyperactivity disorder: a critical appraisal of the cognitive-energetic model. Biol Psychiatry 57 (2005) 1248-1255
94. Serova L., and Sabban E.L. Involvement of alpha 7 nicotinic acetylcholine receptors in gene expression of dopamine biosynthetic enzymes in rat brain. J Pharmacol Exp Ther 303 (2002) 896-903
95. Shytle D.R., Silver A.A., Wilkinson B.J., and Sanberg P. A pilot controlled trial of transdermal nicotine in the treatment of Attention Deficit Hyperactivity Disorder. World J Biol Psychiatry 3 (2002) 150-155
96. Solanto M.V. Dopamine dysfunction in AD/HD: integrating clinical and basic neuroscience research. Behav Brain Res 130 March (2002) 65-71
97. Solanto M.V., and Conners C.K. A dose-response and time-action analysis of autonomic and behavioral effects of methylphenidate in attention deficit disorder with hyperactivity. Psychophysiology 19 (1982) 658-667
98. Solanto M.V., Abikoff H.B., Sonuga-Barke E., Schachar R., Logan G., Wigal T., et al. The ecological validity of delay aversion and response inhibition as measures of impulsivity in AD/HD: a supplement to the NIMH multimodal treatment study of AD/HD. J Abnorm Child Psychol 29 (2001) 215-223
99. Sonuga-Barke E.J., Taylor E., Sembi S., and Smith J. Hyperactivity and delay aversion. I. The effect of delay on choice. J Child Psychol Psychiatry 33 (1992) 387-398
100. Sonuga-Barke E., Dalen L., and Remington B. Do executive deficits and delay aversion make independent contributions to preschool attention-deficit/hyperactivity disorder symptoms?. J Am Acad Child Adolescent Psychiatry 42 (2003) 1335-1338
101. Spencer T., Biederman J., Wilens T., Harding M., O'Donnell D., and Griffin S. Pharmacotherapy of attention-deficit hyperactivity disorder across the life cycle. J Am Acad Child Adolescent Psychiatry 35 (1996) 409-432
102. Spencer T., Biederman J., Wilens T., Faraone S., Prince J., Gerard K., et al. Efficacy of a mixed amphetamine salts compound in adults with attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 58 (2001) 775-782
103. Swanson J.M., Sergeant J.A., Taylor E., Sonuga-Barke E.J.S., Jensen P.S., and Cantwell D.P. Attention-deficit hyperactivity disorder and hyperkinetic disorder. Lancet 351 (1998) 429-433
104. Tannock R. Attention deficit hyperactivity disorder: advances in cognitive, neurobiological, and genetic research. J Child Psychol Psychiatry Allied Disciplines 39 (1998) 65-99
105. Tannock R., Schachar R.J., and Logan G.D. Methylphenidate and cognitive flexibility: dissociated dose effects in hyperactive children. J Abnorm Child Psychol 23 (1995) 253-266
106. Taylor J.R., and Jentsch J.D. Repeated intermittent administration of psychomotor stimulant drugs alters the acquisition of Pavlovian approach behavior in rats: differential effects of cocaine, d-amphetamine and 3,4- methylenedioxymethamphetamine ("Ecstasy"). Biol Psychiatry 50 2 (2001) 137-143
107. Terry Jr. A.V., Risbrough V.B., Buccafusco J.J., and Menzaghi F. Effects of (+/-)-4-[[2-(1-methyl-2-pyrrolidinyl)ethyl]thio]phenol hydrochloride (SIB-1553A), a selective ligand for nicotinic acetylcholine receptors, in tests of visual attention and distractibility in rats and monkeys. J Pharmacol Exp Ther 301 (2002) 284-292
108. Tidey J.W., O'Neill S.C., and Higgins S.T. d-Amphetamine increases choice of cigarette smoking over monetary reinforcement. Psychopharmacology 153 (2000) 85-92
109. Todd R.D., Lobos E.A., Sun L.W., and Neuman R.J. Mutational analysis of the nicotinic acetylcholine receptor alpha 4 subunit gene in attention deficit/hyperactivity disorder: evidence for association of an intronic polymorphism with attention problems. Mol Psychiatry 8 (2003) 103-108
110. van der Meere J., Wekking E., and Sergeant J. Sustained attention and pervasive hyperactivity. J Child Psychol Psychiatry Allied Disciplines 32 (1991) 275-284
111. Volkow N.D., and Insel T.R. What are the long-term effects of methylphenidate treatment?. Biol Psychiatry 54 (2003) 1307-1309
112. Wainer B.H., and Mesulam M.-M. Ascending cholinergic pathways in the rat brain. In: Steriade S., and Biesold D. (Eds). Brain cholinergic systems (1990), Oxford University Press, New York 65-119
113. Warburton D.M., and Rusted J.M. Cholinergic control of cognitive resources. Neuropsychobiology 28 1-2 (1993) 43-46
114. Whalen C.K., Jamner L.D., Henker B., Gehricke J.G., and King P.S. Is there a link between adolescent cigarette smoking and pharmacotherapy for ADHD?. Psychol Addictive Behav 17 4 (2003) 332-335
115. Wilens T.E., Biederman J., Spencer T.J., Bostic J., Prince J., Monuteaux M.C., et al. A pilot controlled clinical trial of ABT-418, a cholinergic agonist, in the treatment of adults with attention deficit hyperactivity disorder. Am J Psychiatry 156 12 (1999) 1931-1937
116. Wilens T.E., Biederman J., Wong J., Spencer T.J., and Prince J.B. Adjunctive donepezil in attention deficit hyperactivity disorder youth: case series. J Child Adolescent Psychopharmacol 10 3 (2000) 217-222
117. Wilens T.E., Verlinden M.H., Adler L.A., Woznia P.J., and West S.A. ABT-089, a neuronal nicotinic receptor partial agonist, for the treatment of attention-deficit/hyperactivity disorder in adults: results of a pilot study. Biol Psychiatry 59 11 (2006) 1065-1070
118. Willcutt E.G., Doyle A.E., Nigg J.T., Faraone S.V., and Pennington B.F. Validity of the executive function theory of attention-deficit/hyperactivity disorder: a meta-analytic review. Biol Psychiatry 57 June (11) (2005) 1336-1346
119. Wonnacott S., Irons J., Rapier C., Thorne B., and Lunt G.G. Presynaptic modulation of transmitter release by nicotinic receptors. Prog Brain Res 79 (1989) 157-163
120. Young J.W., Crawford N., Kelly J.S., Kerr L.E., Marston H.M., Spratt C., et al. Impaired attention is central to the cognitive deficits observed in alpha 7 deficient mice. Eur Neuropsychopharmacol April (2006) [Epub ahead of print]
121. Young J.W., Finlayson K., Spratt C., Marston H.M., Crawford N., Kelly J.S., et al. Nicotine improves sustained attention in mice: evidence for involvement of the alpha7 nicotinic acetylcholine receptor. Neuropsychopharmacology 29 5 (2004) 891-900
122. Zametkin A.J., and Rapoport J.L. Neurobiology of attention deficit disorder with hyperactivity: where have we come in 50 years?. J Am Acad Child Adolescent Psychiatry 26 (1987) 676-686